In the United States, the National Alzheimer’s Project Act was signed into law in January 2011, and the first National Plan appeared just over 12 months later, with five goals: to prevent and effectively treat Alzheimer’s disease by 2025, to enhance care quality and efficiency, to expand support for people with Alzheimer’s disease and their families, to enhance public awareness and engagement, and to improve data to track progress. The National Plan has seen a rise in research funding (currently standing at US$1.4 billion). Individual states, at the same time, began discussions about initiatives aimed at addressing personal, societal, and financial implications of Alzheimer’s disease. An example is from Minnesota where counselling and support for caregivers are provided, with an estimated saving for the state of Minnesota of US$970 million by 2025. In addition, a number of treatment trials are under way, looking at the effect of monoclonal antibodies on Alzheimer’s disease and a series of genetic studies.
PND57 THE SOCIETAL BURDEN OF PRODROMAL ALZHEIMER’S DISEASE IN THE UNITED STATES
